Chemical Information:

• Molecular Formula: C₂₂₃H₃₄₃F₃N₄₆O₇₀
• Molecular Weight: 4845.44 g/mol
• Sequence: YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3
• Molecular Structure: Refer to Certificate of Analysis for detailed structural information.

Description:
GLP3(R) is a synthetic peptide currently under research as a tri-agonist for GLP-1, GIP, and glucagon receptors. It is extensively studied in laboratory environments for its potential influence on metabolic regulation, including energy balance, lipid metabolism, glucose signaling, and related cellular pathways. Provided in lyophilized powder form, GLP3(R) facilitates controlled in vitro investigations into metabolic processes and endocrine signaling.

Research Applications:
GLP3(R) is actively researched for potential roles in:

• Glucose and Insulin Pathways: Investigating signaling mechanisms associated with insulin sensitivity and glucose metabolism in experimental models.
• Energy Balance and Appetite Control: Studying peptide interactions affecting energy intake, appetite regulation, and related metabolic responses.
• Lipid Metabolism: Exploring effects on lipid profiles, fatty acid metabolism, and related metabolic markers in vitro.
• Hepatic Cellular Responses: Evaluating potential roles in liver-related cellular activities, including lipid accumulation, inflammation, and metabolic regulation.

Storage and Handling:

• Store lyophilized powder at -20°C.
• After reconstitution, refrigerate at 2-8°C and use promptly.
• Maintain aseptic handling practices to ensure sterility and product integrity.

Product Specifications:

• Purity: ≥99% (HPLC Verified)
• Appearance: Lyophilized white powder
• Solubility: Soluble in bacteriostatic water

Important Note:
This product is strictly FOR RESEARCH USE ONLY and is intended exclusively for in vitro research and laboratory experimentation by qualified professionals. It is not a drug, food, cosmetic, or dietary supplement, and has not been evaluated by the FDA. This peptide is not intended to diagnose, treat, cure, or prevent any disease. The bodily introduction into humans or animals is strictly prohibited by law. Any misuse, misbranding, or mislabeling is a violation of federal regulations and may result in legal action under applicable federal, state, or local laws.

References:
Referenced scientific publications include:

• Jastreboff, A. M., et al. (2022). “GLP3(R) for the Management of Obesity: A Multi-Receptor Approach.” New England Journal of Medicine.
• Mehta, A., et al. (2023). “Mechanistic Insights into GLP3(R)’s Triple Receptor Agonism.” Diabetes Care.